Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Five Prime Therapeutics, Inc. ("Five Prime" or the "Company") (NASDAQ:FPRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Amgen Inc. (NASDAQ:AMGN). Under the terms of the agreement, Five Prime shareholders will receive only $38.00 in cash for each Five Prime share that they own
The investigation concerns whether the Five Prime Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Amgen is paying too little for the Company.
If you own shares of Five Prime stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/five-prime-therapeutics-inc-nasdaq-fprx/, or call toll free 855-576-4847.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Brodsky & Smith, LLC
View source version on accesswire.com: